Previous 10 | Next 10 |
EWING, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019. The Company reported revenue of $23.3 million and a net loss per share of $0.03 fo...
EWING, N.J., April 18, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019. Management will host a webcast and conference ca...
During the 1992 presidential campaign, candidate Bill Clinton used the slogan “It’s the economy stupid” in the race with opponent George H.W. Bush. Due to a short recession during the time frame, the slogan proved to be prophetic to the final outcome of the election, with ...
Antares Pharma (NASDAQ: ATRS ) receives orphan drug designation (ODD) to evaluate the use of subcutaneous methotrexate (“MTX”) for the treatment of ectopic pregnancy. More news on: Antares Pharma, Inc., Healthcare stocks news, Read more ...
EWING, N.J., March 28, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for the treatment of ectopic pregnancy that meets predefined criteria for medical man...
EWING, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39 th Annual Healthcare Conference on Wednesday March 13, 2019 at 8:40 am Eastern Time. ...
Antares Pharma Inc. (ATRS) Q4 2018 Earnings Conference Call February 28, 2019 8:30 A.M. ET Company Participants Jack Howarth – Vice President-Corporate Affairs Bob Apple – President and Chief Executive Officer Fred Powell – Executive Vice President and Chief ...
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q4 earnings Read more ...
Antares Pharma ( ATRS ) Q4 results : Revenues: $18.8M (+34.3%); Product sales: $14.2M (+29.1%); Licensing and development revenue: $1.1M (-50.0%); Royalties: $3.5M. More news on: Antares Pharma Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ....
Antares Pharma (NASDAQ: ATRS ): Q4 EPS of $0.04 may not be comparable to consensus of -$0.03. More news on: Antares Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...